didn't sanofi/gsk basically retain owkin/relation for their Ai models to build higher probability targets in these deals? The BP stand to make money if the partnership is successful and the deal could end successfully once targets are identified and IP is handed over.
In our case, how would a pharma make money off 434 by simply supporting the research and regulation path without taking a massive piece of sales? 50M and financial support through the next 2-3 years would be great, but where is the prize for the partner if they don't get later revenue?
Anyway, I'm not barracking for management per se, I just can't envision a deal that would be acceptable. Imo.
Let's see how the next 6 months go, hopefully we don't sit at 1.1 for months.
ATH Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)